Literature DB >> 25939303

Dyslipidemia in special ethnic populations.

Jia Pu1, Robert Romanelli2, Beinan Zhao2, Kristen M J Azar2, Katherine G Hastings3, Vani Nimbal2, Stephen P Fortmann4, Latha P Palaniappan3.   

Abstract

This article reviews racial/ethnic differences in dyslipidemia-prevalence of dyslipidemia, its relation to coronary heart disease (CHD) and stroke mortality rates, response to lipid-lowering agents, and lifestyle modification. Asian Indians, Filipinos, and Hispanics are at higher risk for dyslipidemia, which is consistent with the higher CHD mortality rates in these groups. Statins may have greater efficacy for Asians, but the data are mixed. Lifestyle modifications are recommended. Culturally-tailored prevention and intervention should be provided to the minority populations with elevated risk for dyslipidemia and considerably more research is needed to determine the best approaches to helping specific subgroups.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dyslipidemia; Lifestyle modification; Mortality; Prevalence; Racial/ethnic differences; Treatment

Mesh：

Substances：

Year:  2015        PMID： 25939303      PMCID： PMC4421090          DOI： 10.1016/j.ccl.2015.01.005

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN： 0733-8651            Impact factor:   2.213


  67 in total

1.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

2.  ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

Authors:  J E Keskitalo; O Zolk; M F Fromm; K J Kurkinen; P J Neuvonen; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2009-05-27       Impact factor: 6.875

3.  75 years of mortality in the United States, 1935-2010.

Authors:  Donna L Hoyert
Journal:  NCHS Data Brief       Date:  2012-03

4.  Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE).

Authors:  S S Anand; S Yusuf; V Vuksan; S Devanesen; K K Teo; P A Montague; L Kelemen; C Yi; E Lonn; H Gerstein; R A Hegele
Journal:  Indian Heart J       Date:  2000 Nov-Dec

5.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

6.  Coronary heart disease mortality for six ethnic groups in California, 1990-2000.

Authors:  Latha Palaniappan; Yun Wang; Stephen P Fortmann
Journal:  Ann Epidemiol       Date:  2004-08       Impact factor: 3.797

7.  Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients.

Authors:  Yuji Matsuzawa; Toru Kita; Hiroshi Mabuchi; Masunori Matsuzaki; Noriaki Nakaya; Shinichi Oikawa; Yasushi Saito; Jun Sasaki; Kazuaki Shimamoto; Hiroshige Itakura
Journal:  Circ J       Date:  2003-04       Impact factor: 2.993

8.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

Review 9.  A systematic review of physical activity interventions in Hispanic adults.

Authors:  Melinda J Ickes; Manoj Sharma
Journal:  J Environ Public Health       Date:  2012-02-08

Review 10.  Coronary heart disease in south Asians overseas: a review.

Authors:  P M McKeigue; G J Miller; M G Marmot
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437
View more
  12 in total

Review 1.  Interventions to Reduce Ethnic and Racial Disparities in Dyslipidemia Management.

Authors:  Andrew Y Chang; Nadeem E Abou-Arraj; Fatima Rodriguez
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-05-07

Review 2.  Health Disparities of Cardiometabolic Disorders Among Filipino Americans: Implications for Health Equity and Community-Based Genetic Research.

Authors:  Gerald Coronado; Jacqueline Chio-Lauri; Rosheanne Dela Cruz; Youssef M Roman
Journal:  J Racial Ethn Health Disparities       Date:  2021-11-26

3.  Associations Between Prediabetes, by Three Different Diagnostic Criteria, and Incident CVD Differ in South Asians and Europeans.

Authors:  Sophie V Eastwood; Therese Tillin; Naveed Sattar; Nita G Forouhi; Alun D Hughes; Nish Chaturvedi
Journal:  Diabetes Care       Date:  2015-10-20       Impact factor: 19.112

4.  Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial.

Authors:  Yundai Chen; Zuyi Yuan; Juming Lu; Freddy G Eliaschewitz; Alberto J Lorenzatti; Maria Laura Monsalvo; Nan Wang; Andrew W Hamer; Junbo Ge
Journal:  Diabetes Obes Metab       Date:  2019-04-14       Impact factor: 6.577

5.  A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR.

Authors:  Maya S Safarova; Benjamin A Satterfield; Xiao Fan; Erin E Austin; Zhan Ye; Lisa Bastarache; Neil Zheng; Marylyn D Ritchie; Kenneth M Borthwick; Marc S Williams; Eric B Larson; Aaron Scrol; Gail P Jarvik; David R Crosslin; Kathleen Leppig; Laura J Rasmussen-Torvik; Sarah A Pendergrass; Amy C Sturm; Bahram Namjou; Amy Sanghavi Shah; Robert J Carroll; Wendy K Chung; Wei-Qi Wei; QiPing Feng; C Michael Stein; Dan M Roden; Teri A Manolio; Daniel J Schaid; Joshua C Denny; Scott J Hebbring; Mariza de Andrade; Iftikhar J Kullo
Journal:  NPJ Genom Med       Date:  2019-02-11       Impact factor: 8.617

6.  A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.

Authors:  Ji Bak Kim; Woo Hyuk Song; Jong Sung Park; Tae-Jin Youn; Yong Hyun Park; Shin-Jae Kim; Sung Gyun Ahn; Joon-Hyung Doh; Yun-Hyeong Cho; Jin Won Kim
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

7.  An autonomous, but INSIG-modulated, role for the sterol sensing domain in mallostery-regulated ERAD of yeast HMG-CoA reductase.

Authors:  Margaret A Wangeline; Randolph Y Hampton
Journal:  J Biol Chem       Date:  2020-11-22       Impact factor: 5.157

8.  Cardiometabolic risk in young adults from northern Mexico: Revisiting body mass index and waist-circumference as predictors.

Authors:  Abraham Wall-Medrano; Arnulfo Ramos-Jiménez; Rosa P Hernandez-Torres; Rafael Villalobos-Molina; Diana C Tapia-Pancardo; J Rafael Jiménez-Flores; A René Méndez-Cruz; Miguel Murguía-Romero; Itzell A Gallardo-Ortíz; René Urquídez-Romero
Journal:  BMC Public Health       Date:  2016-03-08       Impact factor: 3.295

Review 9.  COVID-19 and ethnicity: A novel pathophysiological role for inflammation.

Authors:  Abhinav Vepa; Joseph P Bae; Faheem Ahmed; Manish Pareek; Kamlesh Khunti
Journal:  Diabetes Metab Syndr       Date:  2020-06-30

Review 10.  Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome.

Authors:  Qinqin Wang; Chun Liang
Journal:  J Cardiovasc Pharmacol       Date:  2020-12       Impact factor: 3.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.